

governance and accountability structure, or by national regulatory authorities aiming to meet the WHO EUL assessment and listing standards for COVID-19 vaccines, which are under development.¹³ Satisfying these conditions is likely to ensure the scientific and ethical integrity of, and public trust in, emergency use authorisations for COVID-19 vaccines, and mitigate the potentially pernicious influence of national politics on global vaccine efforts.

The authors are supported by a Canadian Institutes of Health Research grant (#C150-2019-11). MJS has received contractor or consulting fees from WHO unrelated to the topic of this Comment. SU, RK, and REGU declare no other competing interests.

*Maxwell J Smith, Samuel Ujewe, Rachel Katz,
Ross E G Upshur
maxwell.smith@uwo.ca

Faculty of Health Sciences, Western University, London, ON N6A 5B9, Canada (MJS, SU, RK); and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada (REGU)

- 1 Gostin LO. Russia's Covid-19 vaccine breaches crucial scientific and ethical international standards. *The Moscow Times*, Aug 12, 2020. <https://www.themoscowtimes.com/2020/08/12/russias-covid-19-vaccine-breaches-crucial-scientific-and-ethical-international-standards-a71121> (accessed Oct 29, 2020).
- 2 Lewis D. China's coronavirus vaccine shows military's growing role in medical research. *Nature* 2020; **585**: 494–95.
- 3 Cohen J. Here's how the US could release a COVID-19 vaccine before the election—and why that scares some. *Science* 2020; published online Aug 28. <https://doi.org/10.1126/science.abe5150>.
- 4 Gsell P, Camacho A, Kucharski AJ, et al. Ring vaccination with RVS-V-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. *Lancet Infect Dis* 2017; **17**: 1276–84.
- 5 Maxmen A. Ebola vaccine approved for use in ongoing outbreak. *Nature* 2017; published online May 30. <https://doi.org/10.1038/nature.2017.22024>.
- 6 WHO. Second Ebola vaccine to complement “ring vaccination” given green light in DRC. Sept 23, 2019. <https://www.who.int/news-room/detail/23-09-2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc> (accessed Oct 29, 2020).
- 7 WHO. Four countries in the African region license vaccine in milestone for Ebola prevention. Feb 14, 2020. <https://www.who.int/news-room/detail/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention> (accessed Oct 29, 2020).
- 8 Soucheray S. European Commission grants final approval to Merck's Ebola vaccine. *CIDRAP News*, Nov 11, 2019. <https://www.cidrap.umn.edu/news-perspective/2019/11/european-commission-grants-final-approval-mercks-ebola-vaccine> (accessed Oct 29, 2020).
- 9 European Medicines Agency. Zabdeno. 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/zabdeno> (accessed Oct 30, 2020).
- 10 European Medicines Agency. Mvabea. 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/mvabea> (accessed Oct 30, 2020).
- 11 WHO. Emergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency. July 7, 2015. https://www.who.int/medicines/news/EUAL-vaccines_7July2015_MS.pdf (accessed Oct 29, 2020).
- 12 WHO. WHO publishes Emergency Use Listing procedure and roadmap to make new medical products more readily available during health emergencies. Jan 9, 2020. <https://www.who.int/news-room/detail/09-01-2020-emergency-use-listing-procedure-and-roadmap-health-emergencies> (accessed Oct 29, 2020).
- 13 WHO. Emergency Use Listing of vaccines. 2020. https://www.who.int/medicines/regulation/prequalification/prequal-vaccines/EUL_PQ_Vaccines/en/ (accessed Oct 29, 2020).
- 14 Emanuel EJ, Persad G, Kern A, et al. An ethical framework for global vaccine allocation. *Science* 2020; **369**: 1309–12.

Leveraging the COVID-19 response to end preventable child deaths from pneumonia



Pneumonia kills people, young and old. The world has been reminded of the toll of pneumonia as countries struggle to control the COVID-19 pandemic. COVID-19 has claimed more than 1 million lives so far in 2020,¹ but other infectious diseases have caused pneumonia-related mortality for decades. Although there has been a commendable 54% decline in pneumonia-related deaths among children younger than 5 years since 2000, pneumonia is still the leading infectious cause of child deaths and claims more than 800 000 children's lives every year (WHO Maternal and Child Epidemiology Estimation, unpublished).^{2,3}

Although most children have less illness related to COVID-19 than adults,^{4,5} the potential secondary impacts of the pandemic could cause a reversal in progress in child survival. Robertson and colleagues used a model to estimate that, depending on the degree of severity,

service disruptions, reductions in access to care because of lockdown measures, and increased rates of wasting due to food shortages over 12 months could cause between 506 900 and 2 313 900 additional deaths among children younger than 5 years.⁶ The data suggest that about a third of these preventable deaths could be from pneumonia and newborn sepsis. Review of routine health information and programme data across several countries indicate that since the onset of the pandemic there have been reductions in the numbers of children who attend outpatient services and who receive correct diagnosis and treatment of illnesses and immunisation services (UNICEF and Save the Children, unpublished). Drops in coverage of the pertussis, *Haemophilus influenzae* type b, pneumococcal, and measles vaccines, which all offer protection against pneumonia, put millions of children at risk of severe and potentially fatal infections.⁷

Published Online
November 11, 2020
[https://doi.org/10.1016/S0140-6736\(20\)32348-5](https://doi.org/10.1016/S0140-6736(20)32348-5)

But there is reason for optimism. Measures put in place as part of the COVID-19 response can positively impact health outcomes in the medium and long terms. Mask wearing, physical distancing, and improved hand and cough hygiene will reduce circulation of not only severe acute respiratory syndrome coronavirus 2 but also other viruses and bacterial pathogens that cause severe infections, including pneumonia. Distribution of pulse oximeters and oxygen equipment, together with additional support to front-line health-care services, offers an opportunity to close the gap in access to these essential diagnostic and treatment tools for hypoxaemia, which is often associated with childhood pneumonia deaths.^{8,9} The COVID-19 response is also an opportunity to invest in training of health-care staff to operate and maintain such equipment and safely administer oxygen to patients. The potential impact of these measures on child survival could be considerable, especially for the estimated 4.2 million children every year in low-income and middle-income countries who have pneumonia-related hypoxaemia and require oxygen therapy (UNICEF, Save the Children, and Clinton Health Access Initiative, unpublished).

COVID-19 has underscored why the commitments set out in the 2018 Astana Declaration on Primary Health

Care must be implemented.¹⁰ The pandemic has alerted all governments and communities to the importance of primary health care in controlling the spread of respiratory infections. The world is now focused on the key role of vaccines in protecting lives, livelihoods, and economies. Countries are preparing to procure and distribute COVID-19 vaccines when they become available, and to shore up existing immunisation programmes—an opportunity to also reach the 52% of children globally who still require a full course of pneumococcal pentavalent vaccine (PCV).¹¹ The pandemic has also generated an urgent demand for better data to monitor the pandemic and its effects on the health-care system, including coverage of pulse oximetry, oxygen, and the recommended first-line antibiotics for child pneumonia.

In January, 2020, at the inaugural Global Forum on Childhood Pneumonia, in Barcelona, Spain, government leaders and representatives from UN and multilateral agencies, private companies, non-profit organisations, and academic institutions from over 55 countries endorsed a declaration committing to six strategic actions to accelerate progress in reducing child pneumonia deaths (panel).¹² On World Pneumonia Day, on Nov 12, 2020, it is time to take stock of the key actions the global health community should be taking to support country efforts to strengthen primary health care and health information systems to accelerate progress in preventing child pneumonia infections and deaths.

Routine paediatric health services need to be maintained during and after the COVID-19 pandemic. The global health community and governments must work together to ensure health facilities everywhere are equipped with the basics such as water, electricity, human resources, and essential drugs and supplies. An effective response to the pandemic should build on previous gains such as the rapid scale up of coverage of pentavalent vaccines and PCV.¹¹ The COVID-19 response provides opportunities to increase diagnostic and treatment services for respiratory infections. Those countries that ensure innovations and new technologies provided for COVID-19 respiratory care also meet the health needs of children during and after the pandemic are likely to make rapid progress in reducing child pneumonia deaths. Oxygen supplies can be redeployed to newborn and paediatric wards in health facilities and hospitals and pulse oximeters can be made widely

Panel: Six strategic actions to end pneumonia deaths

1 Develop and implement pneumonia control strategies

Define clear targets, as part of wider child survival strategies and plans to strengthen primary health care and achieve universal health coverage. Pneumonia control efforts must be multisectoral, engaging the sectors of nutrition; air quality; social welfare; water, sanitation, and hygiene; and education. These efforts must take place at the community, national, regional, and global levels.

2 Prioritise vulnerable populations

Focus efforts on reducing exposure to poverty, malnutrition, air pollution, and conflict, and on increasing access to good-quality local health services, including in fragile and humanitarian settings.

3 Finance pneumonia control and treatment adequately

Provide adequate and well coordinated domestic and development spending.

4 Accelerate breakthrough innovations

Increase investment in research and development in areas where cost-effective technologies and systems increase efficiencies and prevent the most pneumonia deaths.

5 Track progress with transparency, accountability, and inclusiveness

Ensure easy access to good-quality and timely data and regular reporting on progress on child mortality, including on the pneumonia target of less than three pneumonia deaths per 1000 livebirths by 2025.¹³

6 Strengthen partnerships

Engage all relevant health and non-health, private, and public actors at global and country levels.

available at primary health-care facilities, where their routine use could improve the diagnosis and treatment of a range of conditions.

The COVID-19 pandemic has garnered the world's attention, but pneumonia and other preventable illnesses, such as malaria, diarrhoea, HIV, tuberculosis, and other infectious diseases, kill millions of children every year. We hope that the way COVID-19 has galvanised immense public health actions in many countries will translate into stronger health systems. We must continue to be a strong voice for children and keep our promise to accelerate the achievement of the Sustainable Development Goal target for child survival. We call on our partners to join us in an effort to use the investments made and lessons learned in the COVID-19 response to make sure everyone benefits, especially children.

HHF is Executive Director of UNICEF. TAG is Director-General of WHO. KW is the Chief Executive of Save the Children UK. LG is Coordinator of the Every Breath Counts Coalition. SB is Chief Executive Officer of Gavi, the Vaccine Alliance. QB is a researcher at the Barcelona Institute for Global Health. PD is Executive Director a.i. of Unitaid. KK is Director of the Bill & Melinda Gates Foundation. AG is Assistant Administrator at the United States Agency for International Development. We declare no competing interests. AG's views are her own and not necessarily those of the United States Agency for International Development or the US Government.

© 2020. United Nations. Published by Elsevier Ltd/Inc/BV. All rights reserved.

**Henrietta H Fore, Tedros Adhanom Ghebreyesus, Kevin Watkins, Leith Greenslade, Seth Berkley, Quique Bassat, Philippe Duneton, Keith Klugman, Alma Golden*
executivedirector@unicef.org

UNICEF, New York, NY 10017, USA (HHF); World Health Organization, Geneva, Switzerland (TAG); Save the Children, London, UK (KW); Every Breath Counts Coalition, New York, NY, USA (LG); Gavi, the Vaccine Alliance, Geneva, Switzerland (SB); Barcelona Institute for Global Health, Barcelona, Spain (QB); Unitaid, Geneva, Switzerland (PD); Bill & Melinda Gates Foundation, Seattle, WA, USA (KK); and United States Agency for International Development, Washington, DC, USA (AG)

- 1 WHO. WHO coronavirus disease (COVID-19) dashboard. 2020. <https://covid19.who.int/> (accessed Nov 4, 2020).
- 2 WHO. Global Health Observatory Data Repository. 2020. <https://apps.who.int/gho/data/view.main.CM1002015REG6-CH9?lang=en> (accessed Nov 4, 2020).
- 3 Interagency Group for Child Mortality Estimation. Levels and trends in child mortality: United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME), report 2020. <https://data.unicef.org/resources/levels-and-trends-in-child-mortality/#:~:text=The%20latest%20Levels%20and%20Trends,estimates%20for%20youth%20aged%2015%E2%80%933> (accessed Nov 4, 2020).
- 4 Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health* 2020; **4**: 653–61.
- 5 Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. *JAMA Pediatr* 2020; published online Sept 25. <https://doi.org/10.1016/j.jamapediatrics.2020.4573>.
- 6 Robertson T, Carter E, Chou VB, Stegmüller A, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. *Lancet Glob Health* 2020; **8**: e901–08.
- 7 WHO, Gavi, the Vaccine Alliance, UNICEF. Agencies call for joint effort to safely deliver routine immunization and proceed with vaccination campaigns against deadly vaccine-preventable diseases. May, 2020. <https://www.gavi.org/news/media-room/least-80-million-children-risk-disease-covid-19-disrupts-vaccination-efforts> (accessed Nov 4, 2020).
- 8 Graham H, Bakare AA, Ayedea AI, et al. Hypoxaemia in hospitalised children and neonates: a prospective cohort study in Nigerian secondary-level hospitals. *EClinicalMedicine* 2019; **16**: 51–63.
- 9 Graham H, Bakare AA, Fashanu C, Wiwa O, Duke T, Falade AG. Oxygen therapy for children: a key tool in reducing deaths from pneumonia. *Pediatr Pulmonol* 2020; **55**: S61–64.
- 10 WHO. Astana Declaration on Primary Health Care. 2018. <https://www.who.int/primary-health/conference-phc/declaration> (accessed Nov 4, 2020).
- 11 WHO. WHO and UNICEF estimates of national immunization coverage. 2020. https://www.who.int/immunization/monitoring_surveillance/data/en/ (accessed Nov 4, 2020).
- 12 The Global Forum on Childhood Pneumonia. Declaration. January, 2020. <https://stoppneumonia.org/wp-content/uploads/2020/02/Final-Global-Forum-Childhood-Pneumonia-Declaration-07.02.2020.pdf> (accessed Nov 4, 2020).
- 13 WHO, UNICEF. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). 2013. https://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia_diarrhoea/en/ (accessed Nov 6, 2020).

Osteoarthritis in 2020 and beyond: a Lancet Commission

Osteoarthritis affects 7% of the global population, more than 500 million people worldwide, with women disproportionately affected by the condition.¹ The number of people affected globally rose by 48% from 1990 to 2019, and in 2019 osteoarthritis was the 15th highest cause of years lived with disability (YLDs) worldwide and was responsible for 2% of the total global YLDs.^{1,2} Although YLDs for osteoarthritis are higher in high Socio-demographic Index (SDI) countries than in middle SDI regions (about 525 vs 220 YLDs per

100 000 population), since 1990 the rate of change in YLDs has been far greater in middle SDI countries than in high SDI countries (89% vs 48%).^{1,2} Osteoarthritis is a leading cause of disability in older adults and the trends of an ageing population and increasing obesity are likely to compound this. These data are concerning but probably underestimate the true size of the problem. Furthermore, the development of treatments for osteoarthritis has not made comparable progress with that for many other musculoskeletal and chronic non-communicable diseases.



Published Online
 November 4, 2020
[https://doi.org/10.1016/S0140-6736\(20\)32230-3](https://doi.org/10.1016/S0140-6736(20)32230-3)